Bionano Genomics BNGOW 深 沪
等待开盘 05-16 09:30:00 美东时间
0.0036
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0036
- 总市值 100.37万
- 52周最高 0.604
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0019
- 委 比 0.00%
- 总股本 2.79亿
- 历史最高 11.82
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.0019
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Transcript: Bionano Genomics Q1 2026 Earnings Conference Call
Bionano Genomics (NASDAQ:BNGO) reported first-quarter financial results on Wedn...
05-14 05:10
Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.95) by 20 percent. This is a 33.91 percent increase over losses of $(1.15) per share from the
05-14 04:11
Bionano Genomics Sees Q2 Sales $7.500M-$7.800M vs $7.520M Est
Bionano Genomics (NASDAQ:BNGO) sees Q2 sales of $7.500 million-$7.800 million vs $7.520 million analyst estimate.
05-14 04:08
Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est
Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $30.000 million-$33.000 million to $30.000 million-$33.000 million vs $32.137 million estimate.
05-14 04:07
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Bionano Genomics Appoints Chairman Al Luderer Interim President, CEO, Effective Immediately
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer
05-07 04:49
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $7 to $6.
04-13 18:54
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
Bionano Genomics announced the publication of a study in the American Journal of Hematology showing that Optical Genome Mapping (OGM) outperforms traditional methods for detecting structural variations and chromosomal abnormalities in multiple myeloma (MM). The study, involving 211 MM samples, found that OGM had a higher success rate, identified additional abnormalities missed by traditional techniques, and provided a more comprehensive view of g...
04-02 12:00
Bionano Genomics Earnings Call: Margin Gains, Growth Test
Bionano Genomics (($BNGO)) has held its Q4 earnings call. Read on for the main ...
03-24 08:02
